- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| 15.10. | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 61 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
| 08.10. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates | 3 | GlobeNewswire (USA) | ||
| 26.09. | Impact BioMedical erhält neues US-Patent für Insektenschutzmittel | - | Investing.com Deutsch | ||
| 26.09. | Impact BioMedical secures new US patent for insect repellent | 1 | Investing.com | ||
| 26.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 82 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
| 20.09. | DSS Inc. buys $2,330 worth of Impact Biomedical shares | 1 | Investing.com | ||
| 19.09. | DSS Inc. buys Impact Biomedical shares worth over $150k | 2 | Investing.com | ||
| 17.09. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 157 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen | |
| 17.09. | Consumer wellness product developer Impact BioMedical prices IPO at $3 low end | 1 | Renaissance Capital | ||
| 16.09. | DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value | 96 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... ► Artikel lesen | |
| 16.09. | Impact BioMedical Prices 1.5 Mln IPO At $3 Per Share | 472 | AFX News | WASHINGTON (dpa-AFX) - Impact BioMedical Inc. (IBO), Monday announced the pricing of its initial public offering of 1.5 million shares at $3.00 per share. The offering is expected to close on... ► Artikel lesen | |
| 16.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces Pricing of Initial Public Offering | 161 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing... ► Artikel lesen | |
| 27.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.08. | IMPACT BIOMEDICAL INC. - 8-A12B/A, Registration of securities | 1 | SEC Filings | ||
| 20.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,220 | +3,55 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| EVOTEC | 10,070 | +1,67 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,68 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| IMMUNOVANT | 26,540 | +1,34 % | Immunovant stock hits 52-week low at $24.66 amid market shifts | ||
| KEROS THERAPEUTICS | 53,84 | -0,46 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| JANUX THERAPEUTICS | 46,500 | -5,04 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| BIONTECH | 99,00 | +1,43 % | Das Übernahme-Karussell kommt in Schwung! Evotec, Vidac Pharma, BioNTech und Formycon im Fokus | Der Sektor BioTech steht heute erneut im Fokus. Mit dem Triton-Einstieg bei Evotec ist wieder ein Deal am Laufen, Investoren sollten nun hellhörig werden. Viele erinnern sich noch an MorphoSys, hier... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,755 | -4,72 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,17 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 42,530 | -2,59 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,78 | +0,03 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| NUVALENT | 92,65 | +1,55 % | Nuvalent-CEO Porter verkauft Aktien im Wert von 2,37 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 36,300 | -3,04 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,44 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen |
Das Unternehmen IMPACT BIOMEDICAL INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,700 Euro und damit -1,82 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.
